• ESCMID
  • CMI
  • EUCAST Newsletter
  • EUCAST News
Search
EUCAST
menu
Back Close
  • About EUCAST
    About EUCAST
    • Overview
    Close
    Organisation
    • Overview
    • Steering Committee
    • General Committee
    • EUCAST Statutes
    • National AST Committees (NAC)
    • Network Laboratories
    • Development Laboratories (EDL)
    • View all
    Subcommittees
    • Overview
    • Antimycobacterial Susceptibility Testing (AMST)
    • Antifungal Susceptibility Testing (AFST)
    • Veterinary Subcommittee on Antimicrobial Susceptibility Testing (VetCAST)
    • Phage Susceptibility Testing Subcommittee (PST)
    • Subcommittee on WGS and Phenotypic AST
    • View all
    Meetings
    • Overview
    • Steering Committee Meetings
    • General Committee Meetings
    Public Consultations
    • Overview
    SOPs
    • Overview
    IVDR and EUCAST
    • Overview
    News
    • Overview
    Publications and Presentations
    • Overview
  • Bacteria
    Bacteria
    • Overview
    Close
    Clinical Breakpoints and Interpretation
    • Overview
    • Clinical Breakpoint Tables
    • Definition of S, I and R
    • When there are no breakpoints?
    • Breakpoints in Brackets
    Guidance Documents
    • Overview
    Important Additional Information
    • Overview
    • Expert Rules
    • Expected Phenotypes
    • Resistance Detection
    MIC and Zone Distributions, ECOFFs
    • Overview
    Methodology and Instructions
    • Overview
    • Disk Diffusion and Quality Control
    • MIC Determination
    • Warnings
    • Media Preparation
    • Disk Diffusion Implementation
    • EUCAST Panels of Phenotypically Defined Strains
      • Overview
      • EUCAST Panel of S. pneumoniae and betalactam agents
      • EUCAST Panel of nine well characterized P. aeruginosa strains
    • IVDR and EUCAST
    • View all
    Rapid AST in blood culture
    • Overview
    • Rapid AST directly from blood culture bottles
    • Methods and Quality Control
    • Breakpoints for Rapid AST
    • Resistance Detection in RAST
    • RAST FAQ
    • RAST MIC:zone diameter correlations
    • RAST Publications
    • View all
    Development of Clinical Breakpoints and ECOFFs
    • Overview
    • About Clinical Breakpoints
    • Setting Breakpoints
    • Public Consultations
    • Rationale Documents
    • MIC:Zone Diameter correlations
    • Technical Notes on Antibacterial Agents
    • View all
    FAQ and EDL Services
    • Overview
    • FAQ
    • EDL MIC Testing Services
  • Mycobacteria (AMST)
    Mycobacteria (AMST)
    • Overview
    Close
    Subcommittee
    • Overview
    Clinical Breakpoints and Interpretation
    • Overview
    MIC distributions and ECOFFs
    • Overview
    Development of Clinical Breakpoints and ECOFFs
    • Overview
    • Public Consultations
    • Rationale Documents
    Methodology and Instructions
    • Overview
    • Reference Method
    • Mycobacteria FAQ
    • Warnings
    • IVDR and EUCAST
    Publications and Presentations
    • Overview
  • Fungi (AFST)
    Fungi (AFST)
    • Overview
    Close
    Subcommittee
    • Overview
    Clinical Breakpoints and Interpretation
    • Overview
    • Clinical breakpoint table
    • When there are no antifungal breakpoints
    Development of clinical breakpoints and ECOFFs
    • Overview
    • Rationale documents
    • Public consultations
    Methodology and Instructions
    • Overview
    • AST of Yeasts
    • AST of Moulds
    • AST of Dermatophytes
    • Warnings
    • Quality Control
    • IVDR and EUCAST
    • View all
    Publications and Presentations
    • Overview
    • Technical Notes on Antifungal Agents
  • VetCAST
    VetCAST
    • Overview
    Close
    Subcommittee
    • Overview
    MIC distributions and ECOFFs
    • Overview
    Development of clinical breakpoints and ECOFFs
    • Overview
    • Rationale Documents
    Publications and presentations
    • Overview
  • Industry
    Industry
    • Overview
    Close
  • Education
    Education
    • Overview
    Close
Search
  • ESCMID
  • CMI
  • EUCAST Newsletter
  • EUCAST News
Frequent searches
  • breakpoints
  • rationale documents
  • expected phenotypes
  • public consultation
  • endocarditis pathogens
  • guidance documents
Suggestions
  1. Home
  2. Search

Search Results

General

A Pragmatic Approach to Susceptibility Classification of Yeasts without EUCAST Clinical Breakpoints

A Pragmatic Approach to Susceptibility Classification of Yeasts without EUCAST Clinical Breakpoints , by Karen Marie Thyssen Astvad, Sevtap Arikan-Akdagli and Maiken Cavling Arendrup.

Get to know more

General consultation on proposed revision of chloramphenicol breakpoints

In a public consultation , EUCAST is asking for views on the proposed revision to chloramphenicol breakpoints. The last date for comments is 11 September, 2022.

Get to know more

Consultation on breakpoint table v 11.0 2021 closed. Comments and responses published

EUCAST consulted on the breakpoint table v. 11.0 (2021) between 4 and 18 December, 2020. The consultation has closed and comments and EUCAST responses are now published.

Get to know more

Reference Method

Reference Method The EUCAST reference method for the Mycobacterium tuberculosis complex is broth microdilution in Middlebrook 7H9. See following documents for further information. EUCAST reference protocol for MIC determination of anti-tuberculous agents against isolates of the Mycobacterium…

Get to know more

General consultation on clinical breakpoints for Vibrio species

General consultation on clinical breakpoints for Vibrio species 1 October - 15 November. Use the form available on the consultation webpage to comment. Queries can be addressed to gunnar.kahlmeter@eucast.org.

Get to know more

Rationale Documents

Rationale Documents EUCAST rationale documents summarise the information on which the EUCAST clinical breakpoints are based. Bedaquiline Rationale for EUCAST clinical breakpoints Version 1.3, 4 July 2019 Download PDF Bedaquiline (TMC207) is a diarylquinoline, a new class of anti-tuberculosis (TB)…

Get to know more

Company Rationale Document template revised

Companies are requested to complete a "company rationale document" to aid the EUCAST process of setting breakpoints for new agents. A template has been available for many years. It is now revised .

Get to know more

Publication in JAC of Vibrio spp methods and material for breakpoints

Publication in Journal of Antimicrobial Chemotherapy: Vibrio species - development of EUCAST susceptibility testing methods and MIC and zone diameter distributions on which to determine clinical breakpoints . Onur Karatuna et al. December 2023.

Get to know more

Advising industry on developing EUCAST MIC and Zone diameter data

The web page " Information for industry " has been supplemented with more information; specifically on the development of disks (content) and of reference MIC and Zone diameter material for EUCAST decisions on breakpoints.

Get to know more

A new version of the breakpoint table (13.1) published. Additional agents for anaerobes.

The breakpoint tables have been updated from 13.0 (1 Jan, 2023) to 13.1 (29 June, 2023). This allows the AST of several additional agents for anaerobic bacteria. There is a matching update of QC tables.

Get to know more
Show more results
© EUCAST 2025. All rights reserved EUCAST.
ContactSitemapPrivacy NoticeDisclaimerCookies

Welcome to the new EUCAST website!

We’ve prepared a short video to help you get familiar with the new layout and features.

Watch the video here